Core Viewpoint - Neuralink, founded by Elon Musk, is set to begin large-scale production of its brain-machine interface technology this year, marking a significant advancement in automated surgical procedures and bringing previously speculative technology into mass production [1][4]. Company Developments - Neuralink has announced that it will automate surgical processes, reducing the insertion time for its devices to 1.5 seconds and cutting manufacturing costs by 95% [4]. - As of September 2025, 12 patients with severe paralysis have successfully implanted Neuralink devices, enabling them to perform tasks such as gaming and social media interaction [5]. - The company raised $650 million (approximately 4.55 billion RMB) in a funding round completed in June [5]. Industry Trends - The brain-machine interface sector is experiencing a surge in interest and investment, with companies like阶梯医疗, 博睿康, and 芯智达 entering clinical validation stages [9]. - The Chinese government has included brain science and related research in its "14th Five-Year Plan," aiming for significant technological breakthroughs by 2027 [10]. - The market for brain-machine interfaces in China is projected to grow from 3.2 billion RMB in 2024 to over 5.5 billion RMB by 2027, with global market estimates reaching $40 billion by 2030 [11]. Market Response - Following Neuralink's announcement, stocks related to brain-machine interfaces surged, with notable increases in companies such as 南京熊猫电子股份 (up 43.69%) and 微创脑科学 (up 16.19%) [2][3]. - A-share market also saw significant gains, with multiple companies hitting the upper limit of their trading range [2]. Future Outlook - Neuralink's roadmap includes plans for motion decoding for patients with spinal injuries and visual encoding for those with vision impairments, potentially addressing mental health issues and enhancing cognitive abilities [6]. - The industry is expected to benefit from technological breakthroughs, policy support, and collaborative ecosystems, with a projected CAGR of 17% from 2025 to 2034 [11].

Group 1: Quantum Technology - The "quantum + supercomputing" integration innovation platform has been established in Chengdu, deploying China's first 550-qubit coherent optical quantum computer, achieving a synergy between classical high-performance computing and quantum computing [7][8] - The deployment of the 550-qubit quantum computer fills the gap in mid-western China for quantum computing capabilities and complements eastern regions like Hefei and Beijing [8] Group 2: Biomanufacturing - The first sugar science key laboratory in Beijing has been approved, co-established by Huaxi Biological and Peking University, focusing on precise manufacturing and functional applications of sugars [10][11] - Huaxi Biological aims to leverage this laboratory to enhance its capabilities in synthetic biology, expanding from hyaluronic acid production to comprehensive sugar biological research [11] Group 3: Hydrogen Energy and Nuclear Fusion - The world's first 30 MW pure hydrogen gas turbine has achieved stable operation, marking a significant step in hydrogen energy transitioning from a "power consumer" to a "grid regulator" [12][14] - The EAST nuclear fusion device has confirmed the existence of a density-free zone, providing critical physical evidence for efficient fusion reactor operation [18][19] - The ITER correction coil procurement package has been fully manufactured, showcasing China's 100% independent research and development capabilities in key components for nuclear fusion [22] Group 4: Brain-Computer Interface - Neuralink plans to begin mass production of brain-computer interface devices in 2026, aiming to automate surgical procedures and enhance device performance [24][25] - The "Beijing Brain One" system has been implanted in five spinal cord injury patients, with plans for clinical trials to start in mid-2026 [28][29] - The "Guangdong-Hong Kong-Macao Greater Bay Area Brain Science and Central Nervous System AI Innovation Alliance" has been launched, with a total fund of 1.16 billion yuan for brain science projects [30] Group 5: Embodied Intelligence - Woan Robot has been listed on the Hong Kong Stock Exchange, focusing on household scenarios with plans to launch a humanoid household robot in January 2026 [32][33] - The "Shangwei Qiyuan" brand has entered the personal robot market with the release of the world's first small-sized humanoid robot, emphasizing its application in research and interaction [37][38] Group 6: Future Industry Catalysts - A table has been compiled detailing key catalytic events for six future industries in 2026, including important conferences and technological milestones [40][41]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant activity and potential growth, driven by technological advancements and policy support, with expectations for commercialization by 2026 [1][4]. Group 1: Market Activity - On the first trading day of 2026, BCI-related stocks showed strong performance, with companies like Beiyikang and Sanbo Brain Science reaching their daily price limits [1]. - The market is expected to benefit from Neuralink's anticipated large-scale production and automated surgical solutions, which could enhance efficiency and reduce costs [1][3]. Group 2: Technological Developments - Neuralink plans to begin large-scale production of BCI devices in 2026, utilizing a new surgical method that avoids traditional invasive techniques [1][3]. - Merge Labs, co-founded by OpenAI's CEO, is focusing on non-invasive ultrasound technology to interpret brain signals without implanting electrodes [3]. Group 3: Industry Growth Projections - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034 [4]. - The BCI industry is positioned for rapid expansion due to technological breakthroughs, supportive policies, and the integration of robotics [4][5]. Group 4: Competitive Landscape - The BCI field is highly competitive, with various companies engaged in clinical trials and product development across invasive, semi-invasive, and non-invasive categories [5][6]. - Domestic companies like Brain Tiger Technology are making significant advancements, while others are developing products for medical monitoring and rehabilitation [6]. Group 5: Policy and Regulatory Environment - Recent policies are clarifying standards for BCI technologies, facilitating quicker integration into healthcare systems once approved [6]. - The establishment of industry standards by the National Medical Products Administration is expected to enhance regulatory compliance and market entry for BCI products [6]. Group 6: Long-term Outlook - There is a positive long-term outlook for leading companies that possess technological and regulatory advantages, as well as those that can leverage existing resources to accelerate BCI development [7].

1月5日， 脑机接口板块持续大涨，截至发稿，板块指数涨幅已超11%。 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 编辑丨瑜见 倍益康30%涨停，美好医疗、三博脑科、熵基科技、翔宇医疗、诚益通等10股20%涨停，创新医疗、荣 泰健康、南京熊猫、三七互娱等涨停。 | 代码 | 名称 | 式唱 | 息金额 | 息而值 | 现价 | | --- | --- | --- | --- | --- | --- | | 920199 | 倍益康 | +29.98% | 1.96 Z | 30.62 G | 44.96 | | 688767 | 博拓生物 | +20.01% | 6.27 Z | 67.71 Z | 45.34 | | 301293 | 三博脑科 | +20.01% | 7.04Z | 1 45.8亿 | 70.78 | | 301363 | 美好医疗 | +20.00% | 1.98 Z | 164.2 乙 | 28.86 | | 301330 | শ্ব # 技 | +20.00% | 7.25 Z | 93.34 Z | 39.66 | | 300887 | 谱尼测试 | + ...

Group 1: A-Share Market Performance - The A-share market opened higher on January 5, with all three major indices rising collectively, and the Shanghai Composite Index returning to the 4000-point mark for the first time in 34 trading days [1] - Insurance and precious metals sectors led the gains, with New China Life Insurance (601336) rising nearly 8% to reach a historical high, while China Ping An, China Pacific Insurance (601601), China Life Insurance (601628), and China Reinsurance (601319) also saw significant increases [1] Group 2: Brain-Computer Interface Sector - The brain-computer interface concept experienced a surge, with several companies hitting the daily limit up, including Meihua Medical (301363) and Aipeng Medical (300753), both reaching the 20% limit up, alongside other companies like Botao Bio and Aerospace Changfeng (600855) [1] - The surge was influenced by Elon Musk's announcement regarding Neuralink's plans to significantly increase brain device production by 2026 and innovate in implantation methods [1] Group 3: Lithium Mining and Storage Chip Sector - The lithium mining sector saw a strong rally, particularly in the salt lake lithium extraction direction, with Salt Lake Co. (000792) hitting the daily limit up and reaching a three-and-a-half-year high, while Cangge Mining (000408) rose nearly 6% to set a new historical high [2] - Storage chip concepts also strengthened, with Jiangbolong (301308) rising over 14% and Shanghai Xinyang (300236) increasing over 12%, driven by significant investments in AI infrastructure by major North American cloud service providers [2] Group 4: Storage Chip Market Forecast - Guojin Securities predicts a continued supply-demand imbalance in the global storage chip market for 2026, with DRAM supply expected to grow by 15% to 20% and demand by 20% to 25%, while NAND supply is projected to increase by 13% to 18% and demand by 18% to 23% [3] - The consumption of DRAM and NAND flash in the server sector is expected to surge by 40% to 50% year-on-year, with even faster growth in AI server applications [3] - Price forecasts for storage contracts indicate a potential increase of 30% to 40% in Q1 2026, with DDR5 RDIMM memory prices expected to rise over 40% and NAND flash prices anticipated to see double-digit percentage increases [3]

1月5日， 脑机接口板块持续大涨，截至发稿，板块指数涨幅已超11%。 倍益康30%涨停，美好医疗、三博脑科、熵基科技、翔宇医疗、诚益通等10股20%涨停，创新医疗、 荣泰健康、南京熊猫、三七互娱等涨停。 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 编辑丨瑜见 | 代码 | 名称 | 涨幅量 | 息金额 | 息市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 920199 | 倍益康 | +29.98% | 1.96 Z | 30.62 乙 | 44.96 | | 688767 | 博拓生物 | +20.01% | 6.27 Z | 67.71 Z | 45.34 | | 301293 | 三博脑科 | +20.01% | 7.04 Z | 145.8亿 | 70.78 | | 301363 | 美好医疗 | +20.00% | 1.98 乙 | 164.2 乙 | 28.86 | | 301330 | 腐基科技 | +20.00% | 7.25 Z | 93.34 乙 | 39.66 | | 300887 | 谱尼测试 | +20 ...

一、行情表现 1月5日，脑机接口板块开盘大涨。三博脑科（20CM）、岩山科技、创新医疗、南京熊猫等集体一字板，塞力医疗、盈趣科技、翔宇医疗（20CM）、荣泰 健康、国际医学、爱朋医疗（20CM）、熵基科技（20CM）、麦澜德（20CM）、诚益通（20CM）、伟思医疗（20CM）、迈普医学（20CM）等集体涨 停。 | 脑科学 +12.41% | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 理由 | | 马斯克旗下脑机接口公司2026年将启动脑机接口设备"大规模生产" | | | | | | 股票名称 | 最新价 = | 涨跌幅 = | 涨停时间 = | 换手率 = | 流通市值 ◆ | 解读 | | 三博脑科 | 70.78 | +20.01% | 09:25:00 | 6.18% | 113.92 乙 | 公司是以神经专科为特色的医疗服务集 | | 301293.SZ | | | | | | 院,其中神经专科医院4家,综合性医院 | | 美好医疗 | | | | | 107.71亿 | 公司正与下游脑机接口客户开展产品合 批量出货的商业 ...

Group 1 - The brain-computer interface concept has seen significant market activity, with multiple stocks experiencing substantial gains [1] - Companies such as Botao Bio and Aerospace Changfeng have reached their daily price limit, indicating strong investor interest [1] - Nearly 20 stocks, including Beiyikang and Sanbo Brain Science, have also hit their daily price limit, showcasing a broad rally in the sector [1] Group 2 - Other notable performers include Guanhao Bio, Dineike, Zhongke Information, Hanwei Technology, and Daoshi Technology, all of which have seen stock increases exceeding 10% [1]

| 上证指数 | | 4004.12 | +35.28 | +0.89% | | --- | --- | --- | --- | --- | | 000001 | | | | | | 创业板指 | M | 3267.86 | +64.68 | +2.02% | | 399006 | | | | | | 深证成指 | | 13739.89 | +214.87 | +1.59% | | 399001 | M | | | | | 科创50 | | 1389.18 | +44.98 | +3.35% | | 000688 | | | | | | 北证50 | | 1452.48 | +12.05 | +0.84% | | 899050 | | | | | | 沪深300 | | 4696.32 | +66.38 | +1.43% | | 000300 | N | | | | | F证50 | | 3084.01 | +52.89 | +1.74% | | 000016 | | | | | 格隆汇1月5日｜A股主要指数拉升，创业板指涨超2%，深成指涨1.59%，沪指涨0.89%。脑机接口板块 掀涨停潮，保险、半导体芯片 ...

1月5日，A股迎来2026年的首个交易日，三大指数集体高开。沪指高开0.46%，深成指高开0.80%，创业 板指高开0.84%，A股迎来开门红。 板块方面，人脑工程、贵金属、石油石化等板块指数涨幅居前。 其中，脑机接口概念表现活跃，创新医疗涨停，美好医疗、三博脑科20cm涨停，倍益康、爱朋医疗、 翔宇医疗涨超10%。消息面上，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开 始对脑机接口设备进行"大规模生产"。 另外，早盘商业航天概念大面积高开，金风科技、雷科防务、联创光电等多股涨停，久之洋、北斗星 通、中国卫星、顺灏股份等高开超5%。消息面上，12月31日，上交所官网显示，蓝箭航天科创板IPO获 受理，正式冲刺"商业火箭第一股"。 值得一提的是，就在明日，A股市场还将迎来首只上市新股，同日还有两只新股开启申购。 随着马年春节的临近，资本市场将会怎么走？各大券商也纷纷做出预测。 中信证券称，增量资金入市不会是2026年市场迈上一个新台阶的主要因素。2026年最大的预期差来自于 外需与内需的平衡，对外"征税"、补贴内需应是大势所趋，今年是个重要的开端。站在开年，考虑到去 年末的资金热 ...